{"schema_version":"1","generated_at":"2026-10-28T22:21:31.247Z","data_as_of":null,"url":"https://www.findmykol.com/kol/timothy-voorhees","json_url":"https://www.findmykol.com/kol/timothy-voorhees/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"timothy-voorhees","name":"Timothy Voorhees","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"The Ohio State University Comprehensive Cancer Center","institution_url":"https://www.findmykol.com/institution/the-ohio-state-university","city":"Columbus","state":"OH","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1467870675","orcid":"0000-0001-7603-6454","openalex":"A5085820043"},"summary":"Timothy Voorhees is a Hematology physician affiliated with The Ohio State University Comprehensive Cancer Center. OpenAlex indexes 157 publications with 1,015 citations (h-index 15); ClinicalTrials.gov lists 3 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":157,"cited_by_count":1015,"h_index":15,"latest_activity_year":2026,"source":"works"},"trials":{"count":3,"shown":3,"withheld":2,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06741072","title":"BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants","phase":"PHASE1","status":"RECRUITING","role":"Overall official","sponsor":"Ohio State University Comprehensive Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT06741072","trial_url":"https://www.findmykol.com/trial/NCT06741072"},{"nct":"NCT06672705","title":"Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders","phase":"PHASE1","status":"RECRUITING","role":"Overall official","sponsor":"Timothy Voorhees","source_url":"https://clinicaltrials.gov/study/NCT06672705","trial_url":"https://www.findmykol.com/trial/NCT06672705"},{"nct":"NCT06031194","title":"Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","role":"Overall official","sponsor":"Ohio State University Comprehensive Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT06031194","trial_url":"https://www.findmykol.com/trial/NCT06031194"}],"source":"trials"},"payments":{"company_count":13,"program_years":{"first":2021,"last":null},"rows_total":16,"shown":3,"withheld":13,"rows":[{"payer":"Ipsen Biopharmaceuticals, Inc","program_year":2025,"amount_usd":5460,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1467870675"},{"payer":"RECORDATI_RARE_DISEASES_INC.","program_year":2025,"amount_usd":1360,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1467870675"},{"payer":"Janssen Research & Development, LLC","program_year":2025,"amount_usd":146.14,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1467870675"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1467870675","source":"payments"},"prescribing":{"data_year":2024,"areas_total":4,"areas_shown":3,"areas":[{"area":"Anti-infectives","share_pct":42.3,"classes_total":2,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":30.1,"drugs":[{"name":"Valacyclovir","share_pct":100}],"max_beneficiaries":11},{"class":"Short-acting sulfonamides","setting":"prescribed","share_pct":12.2,"drugs":[{"name":"Sulfamethoxazole-Trimethoprim","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":32.5,"classes_total":1,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":32.5,"drugs":[{"name":"Brukinsa","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":15.4,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":15.4,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":65.3,"facility_pct":34.7},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":2026,"last":2026},"rows_total":1,"shown":1,"withheld":0,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"R01CA308586","title":"Epstein-Barr Virus positive post-transplant lymphoproliferative disorders: identifying viral and host variables to predict risk and therapeutic responses","fiscal_year":2026,"amount_usd":"366965","organization":"OHIO STATE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/R01CA308586"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study","year":2026,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2025019115","status":"verified"},{"title":"Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies","year":2025,"journal":"Journal of Hematology & Oncology","source_url":"https://doi.org/10.1186/s13045-025-01676-4","status":"verified"},{"title":"Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers","year":2025,"journal":"Blood Cancer Journal","source_url":"https://doi.org/10.1038/s41408-025-01257-1","status":"verified"},{"title":"Isolated oral CD30+/CD4+ CAR+ T cell lymphoma in long-term remission after radiotherapy","year":2025,"journal":"Molecular Therapy","source_url":"https://doi.org/10.1016/j.ymthe.2025.08.043","status":"verified"},{"title":"A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-265","status":"verified"}],"source":"works"},"contact":{"address_1":"460 W 10TH AVE FL 5","city":"Columbus","state":"OH","zip":"432101240","phone":"614-293-3196","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1467870675","source":"identity"},"similar":[{"name":"Gregory Otterson","slug":"gregory-otterson","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gregory-otterson","json_url":"https://www.findmykol.com/kol/gregory-otterson/profile.json"},{"name":"Raphael Pollock","slug":"raphael-pollock","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/raphael-pollock","json_url":"https://www.findmykol.com/kol/raphael-pollock/profile.json"},{"name":"Steven Clinton","slug":"steven-clinton","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/steven-clinton","json_url":"https://www.findmykol.com/kol/steven-clinton/profile.json"},{"name":"Claire Verschraegen","slug":"claire-verschraegen","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/claire-verschraegen","json_url":"https://www.findmykol.com/kol/claire-verschraegen/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Jeffrey Miller","slug":"jeffrey-miller","institution":"University of Minnesota Medical School","specialty":"Hematology","url":"https://www.findmykol.com/kol/jeffrey-miller","json_url":"https://www.findmykol.com/kol/jeffrey-miller/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":2,"payments":13,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-08-11","provider_certified":"2025-08-11","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}